Exclusive: A quarter of Americans are hesitant about a coronavirus
vaccine - Reuters/Ipsos poll
Send a link to a friend
[May 21, 2020]
By Joseph Ax and Julie Steenhuysen
(Reuters) - A quarter of Americans have
little or no interest in taking a coronavirus vaccine, a Reuters/Ipsos
poll published on Thursday found, with some voicing concern that the
record pace at which vaccine candidates are being developed could
compromise safety.
While health experts say a vaccine to prevent infection is needed to
return life to normal, the survey points to a potential trust issue for
the Trump administration already under fire for its often contradictory
safety guidance during the pandemic.
Some 36% of respondents said they would be less willing to take a
vaccine if U.S. President Donald Trump said it was safe, compared with
only 14% who would be more interested.
Most respondents in the survey of 4,428 U.S. adults taken between May 13
and May 19 said they would be heavily influenced by guidance from the
Food and Drug Administration or results of large-scale scientific
studies showing that the vaccine was safe.
Less than two-thirds of respondents said they were "very" or "somewhat"
interested in a vaccine, a figure some health experts expected would be
higher given the heightened awareness of COVID-19 and the more than
92,000 coronavirus-related deaths in the United States alone.
"It's a little lower than I thought it would be with all the attention
to COVID-19," said Dr. William Schaffner, an infectious disease and
vaccine expert at Vanderbilt University Medical Center in Nashville. "I
would have expected somewhere around 75 percent."
Fourteen percent of respondents said they were not at all interested in
taking a vaccine, and 10% said they were not very interested. Another
11% were unsure.
Studies are underway, but experts estimate that at least 70% of
Americans would need to be immune through a vaccine or prior infection
to achieve what is known as "herd immunity," when enough people are
resistant to an infectious disease to prevent its spread.
Trump has vowed to have a vaccine ready by year's end, although they
typically take 10 years or longer to develop and test for safety and
effectiveness. Many experts believe a fully tested, government-approved
vaccine will not be widely available until mid-2021 at the earliest.
There are more than 100 COVID-19 vaccine candidates in development
globally, including some already in human clinical trials. Earlier this
week, U.S. biotech Moderna Inc announced potentially promising
preliminary results from just eight individuals who took part in a
safety study.
Among those respondents who expressed little or no interest in a
coronavirus vaccine, nearly half said they were worried about the speed
with which they are being developed. More than 40% said they believe the
vaccine is riskier than the disease itself.
MISINFORMATION HURDLE
Overall, 84% of respondents said vaccines for diseases such as measles
are safe for both adults and children, suggesting that people hesitant
to take a coronavirus vaccine might reconsider, depending on safety
assurances they receive.
For example, among those who said they were "not very" interested in
taking the vaccine, 29% said they would be more interested if the FDA
approved it.
[to top of second column]
|
Small bottles labeled with a "Vaccine COVID-19" sticker and a
medical syringe are seen in this illustration taken taken April 10,
2020. REUTERS/Dado Ruvic/Illustration/File Photo
Some experts have said the White House's emphasis on speed – its
vaccine effort is called "Operation Warp Speed" – could leave people
worried that safety was being sacrificed for swiftness.
In addition, misinformation about vaccines has grown more prevalent
on social media during the pandemic, according to academic
researchers.
"It's not surprising a significant percentage of Americans are not
going to take the vaccine because of the terrible messaging we've
had, the absence of a communication plan around the vaccine and this
very aggressive anti-vaccine movement," said Peter Hotez, dean of
the National School of Tropical Medicine at Baylor College of
Medicine, where he is developing a vaccine.
The poll underscores how the country's deepening polarization has
affected people's view of the pandemic.
Nearly one in five Republicans say they have no interest in a
vaccine, more than twice the proportion of Democrats who said the
same.
Trump, a Republican, has offered mixed messages during the outbreak.
He has at times downplayed the seriousness of the pandemic and
encouraged public protests against his government's own stay-at-home
guidelines intended to slow the pathogen's spread.
He has also urged Americans to try unproven treatments for COVID-19,
such as the malaria drug hydroxychloroquine, which he said on Monday
he has taken for weeks despite warnings about its use from the FDA
and other health experts.
The poll responses varied among certain demographic groups. Only
half of black Americans, who represent a disproportionate percentage
of coronavirus deaths, said they were somewhat or very interested in
a vaccine, perhaps reflecting memories of an infamous U.S.
government study that left black men deliberately untreated for
syphilis.
College-educated white women - a politically important demographic
that has moved sharply away from the Republican Party during the
Trump era - were particularly concerned about how quickly the
vaccine is being developed. More than 40% said Trump's reassurance
would make them less willing to take it.
The Reuters/Ipsos poll was conducted online, in English, throughout
the United States and had a credibility interval, a measure of
precision, of plus or minus 2 percentage points.
(Reporting by Joseph Ax in West Stockbridge, Massachusetts, and
Julie Steenhuysen in Chicago; additional reporting by Grant Smith in
Jersey City, N.J., editing by Ross Colvin and Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |